Ionis insider plans sale of 10,000 shares

Ionis Pharmaceuticals (symbol IONS) has an insider planning to sell 10,000 shares of common stock through broker Stifel Nicolaus & Company on or around February 11, 2026 on the Nasdaq market.

Rhea-AI Filing Summary

Ionis Pharmaceuticals (symbol IONS) has an insider planning to sell 10,000 shares of common stock through broker Stifel Nicolaus & Company on or around February 11, 2026 on the Nasdaq market. The filing lists an aggregate market value of $827,400 for these planned sales.

The securities relate to common stock originally acquired on January 15, 2017 as restricted stock units granted by the issuer as equity compensation. The notice also states that the person signing does not know of any undisclosed material adverse information about the issuer’s current or prospective operations.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Rule 144 filing for Ionis (IONS) disclose?

The Rule 144 filing discloses a planned sale of 10,000 Ionis common shares. The shares are to be sold on Nasdaq through Stifel Nicolaus & Company, with an indicated aggregate market value of $827,400 for the proposed transaction.

How many Ionis (IONS) shares are planned to be sold under this notice?

The notice covers a planned sale of 10,000 shares of Ionis common stock. These shares are part of the company’s total 161,974,393 shares outstanding and are expected to be sold on the Nasdaq exchange through Stifel Nicolaus & Company.

What is the reported market value of the Ionis (IONS) shares to be sold?

The filing reports an aggregate market value of $827,400 for the 10,000 Ionis common shares to be sold. This value reflects the seller’s estimate at the time of the notice and is tied specifically to this planned Rule 144 transaction.

How and when were the Ionis (IONS) shares originally acquired?

The securities were originally acquired on January 15, 2017 as restricted stock units. The filing states they were granted by the issuer as equity compensation, with 78,321 securities acquired and payment dated the same day, categorized as equity compensation.

Which broker and exchange are involved in the Ionis (IONS) planned sale?

The filing lists Stifel Nicolaus & Company Inc. as the broker handling the planned sale. It identifies Nasdaq as the securities exchange where the 10,000 Ionis common shares are expected to be sold under this Rule 144 notice.

What representations does the seller make in this Ionis (IONS) Rule 144 notice?

The seller represents that they do not know any material adverse information about the issuer’s current or prospective operations that has not been publicly disclosed. This representation is part of the standard Rule 144 notice language included in the form.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/11/2026 - 04:02 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001073385
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	IONIS PHARMACEUTICALS INC
SEC File Number	000-19125
Address of Issuer	2855 GAZELLE COURT CARLSBAD CALIFORNIA 92010
Phone	7609319200
Name of Person for Whose Account the Securities are To Be Sold	PARSHALL B LYNNE
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Stifel Nicolaus & Company Inc 501 N Broadway St. Louis MO 63102	10000	827400.00	161974393	02/11/2026	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	01/15/2017	Restricted Stock Units	Issuer			78321	01/15/2017	Equity Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	02/11/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	05/06/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Luca Lotito, as a duly authorized representative of STIFEL, as attorney-in-fact for Lynne Parshall
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)